Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
REDWOOD CITY, Calif., May 01, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.
- A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference on Wednesday, May 3rd at 10:40 a.m. EDT taking place in Boston, MA.
- A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18th at 8:40 a.m. PDT taking place in Las Vegas, NV.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
